Fulcrum Therapeutics, Inc.

US$3.70As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:FULCHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (16.59%)
Div yield —
ROE (32.38%)
Biotechnology
Beta (5Y) 2.77
PE TTM —
TSR TTM (57.71%)
Mkt cap US$282.3M
ROIC (20.13%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.31
16.55%
(39.41%)
Sell 3|6|1|1|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.06
0.06
0.06
0.06
24.24%
15.96%
6.72%
(4.64%)
Revenue$M
15.86
15.62
15.42
15.36
20.66%
12.39%
5.23%
2.14%
Peers (US$282.3M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.447
0.137
0.144
EBIT/Intx
1.380
1.122
0.987
Own earn%
881.10
20.21
29.18
Sh yield%
12.81
62.13
62.04
Owners
Insiders/Inst%
11.18
87.33
Short interest%
2.81
SBC / revenue%
2.10
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
22–28
$1 testx
0.0
Incr. ROIC%
24